Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

989 Beyond CRS: emerging longitudinal safety management strategies for T-cell–engaging bispecific antibodies

  • Nicholas A Zorko1
  • Rifeta Kajdic Hodzic2
  • Kirollos S Hanna3
  • Zahra Mahmoudjafari4
  • Jeffrey M Clarke5
  • Jean L Koff6
  • Muhamed Baljevic7
  • Robert Mancini8
  • Donald C Moore9
  • Megan May10
  • Sarah Hudson-Disalle11
  • Elana Plotkin12
3 more authors
  • Molly McHale12
  • Bianca Alvarez12
  • Caroline Offit12
12 affiliations
  1. 1University of Minnesota, Minneapolis, MN, USA
  2. 2Association of Cancer Care Centers (ACCC), Meridian, ID, USA
  3. 3Mayo Clinic College of Medicine, Rochester, MN, USA
  4. 4University of Kansas Health System, Mission, KS, USA
  5. 5Duke University, Durham, NC, USA
  6. 6Winship Cancer Institute of Emory University, Atlanta, GA, USA
  7. 7Vanderbilt University Medical Center, Nashville, TN, USA
  8. 8St. Luke’s Cancer Institute, Boise, ID, USA
  9. 9Levine Cancer Institute Atrium Cancer Center, Pineville, NC, USA
  10. 10Baptist Health Lexington, Lexington, KY, USA
  11. 11The Ohio State University Comprehensive Cancer Center – The James, Columbus, OH, USA
  12. 12Association of Cancer Care Centers (ACCC), Rockville, MD, USA
Open at sourcePDFDOICite

Related

  1. Non‐Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis
    Sohaib Irfan, Harshit Khosla, Saad Nasir +5
    Hematological oncologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.
    Xiaojing Wu, Clara Effenberger, Yosuke Matsushita +7
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC
  3. LIF and let die: Generation, mechanistical and structural characterization of bispecific antibodies triggering leukemia inhibitory factor (LIF) receptor activation independent of the cytokine LIF
    Julia Harwardt, Silke Pudewell, Kristina Keil +12
    Journal of Biological ChemistryPeer-reviewedCC BY 4.0OncologyCrossref
  4. CD3-engaging bispecific antibodies convert human regulatory T cells into cytotoxic effectors
    J. J. Michel, J. H. Frenking, A. Metzler +23
    medRxivPreprintAll rights reservedFull textOncologymedRxiv
  5. Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice
    Xia Li, Hao Peng, Feng Hao +3
    iSciencePeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCell PressCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zorko2026beyond,
  title = {{989 Beyond CRS: emerging longitudinal safety management strategies for T-cell–engaging bispecific antibodies}},
  author = {Nicholas A Zorko and Rifeta Kajdic Hodzic and Kirollos S Hanna and Zahra Mahmoudjafari and Jeffrey M Clarke and Jean L Koff and Muhamed Baljevic and Robert Mancini and Donald C Moore and Megan May and Sarah Hudson-Disalle and Elana Plotkin and Molly McHale and Bianca Alvarez and Caroline Offit},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0989},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0989},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 989 Beyond CRS: emerging longitudinal safety management strategies for T-cell–engaging bispecific antibodies
AU  - Nicholas A Zorko
AU  - Rifeta Kajdic Hodzic
AU  - Kirollos S Hanna
AU  - Zahra Mahmoudjafari
AU  - Jeffrey M Clarke
AU  - Jean L Koff
AU  - Muhamed Baljevic
AU  - Robert Mancini
AU  - Donald C Moore
AU  - Megan May
AU  - Sarah Hudson-Disalle
AU  - Elana Plotkin
AU  - Molly McHale
AU  - Bianca Alvarez
AU  - Caroline Offit
PY  - 2026
DA  - 2026/11/09
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0989
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0989
SN  - 2051-1426
ER  -